J&J's Prezista better than Abbott's Kaletra in fighting HIV

09/19/2007 | Bloomberg

Johnson & Johnson's HIV treatment Prezista reduced the amount of the virus to undetectable levels in 84% of patients, as compared with Abbott Laboratories' Kaletra, which lowered the amount in only 78% of patients, researchers report. However, such findings do not imply that Prezista should be recommended in place of Kaletra as a first-line protease inhibitor, a co-author of the study said.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC